ADVR Interview mit CEO - 500 Beiträge pro Seite
eröffnet am 07.07.00 15:52:41 von
neuester Beitrag 14.02.01 18:12:56 von
neuester Beitrag 14.02.01 18:12:56 von
Beiträge: 41
ID: 178.305
ID: 178.305
Aufrufe heute: 0
Gesamt: 689
Gesamt: 689
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 00:55 | 586 | |
| vor 1 Stunde | 311 | |
| gestern 11:56 | 285 | |
| gestern 23:08 | 186 | |
| gestern 21:36 | 171 | |
| gestern 23:36 | 133 | |
| heute 03:42 | 133 | |
| gestern 18:12 | 124 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.503,00 | +0,34 | 294 | |||
| 2. | 2. | 174,72 | -1,74 | 108 | |||
| 3. | 3. | 10,230 | +447,06 | 107 | |||
| 4. | 4. | 0,1935 | +2,38 | 77 | |||
| 5. | 7. | 0,9600 | -14,29 | 70 | |||
| 6. | 5. | 4,1725 | -5,17 | 64 | |||
| 7. | 6. | 1,1100 | -3,48 | 60 | |||
| 8. | 8. | 5,9840 | -1,55 | 47 |
Feedback
ein Interview mit CEO Hirschmann gibt es auf
http://www.8ung.at/zockstocks
(erforderlich ist der Windows Mediaplayer)
Quelle: http://www.ceocast.com
morchel
http://www.8ung.at/zockstocks
(erforderlich ist der Windows Mediaplayer)
Quelle: http://www.ceocast.com
morchel
Ich glaube, ADVR wird weiter steigen, auf dem 38. Jahresmeeting der IDSA am 7.-10.9.00 in New Orleans werden 2 Vortraege ueber Produkt R und die Wirkung auf HIV und opportunistische Erkrankungen ( z. B. Herpes) gehalten. Quelle: quote.yahoo.
Hirschman, CEO von ADVR wird alles dran setzen die Erlaubnis fuer Phase1 von der FDA zu bekommen, er ist da sehr optimistisch und ich auch, der Kurs wird abgehen. Auf raging-bull gibt es Geruechte, dass sich eine Pharmafirma an ADVR beteiligen koennte, weiss allerdings nicht, ob da was serioeses dran ist.
Good luck Glurac
Hirschman, CEO von ADVR wird alles dran setzen die Erlaubnis fuer Phase1 von der FDA zu bekommen, er ist da sehr optimistisch und ich auch, der Kurs wird abgehen. Auf raging-bull gibt es Geruechte, dass sich eine Pharmafirma an ADVR beteiligen koennte, weiss allerdings nicht, ob da was serioeses dran ist.
Good luck Glurac
Vergangene Woche sah es nach einem "3-day-play" aus. Am Freitag konnte sich der Kurs aber etwas festigen. Kommende Woche wird sich zeigen, ob der Kurs auf einem Niveau von 0,55$ halten wird.
HIVC zum Vergleich sank nach eklatantem Anstieg trotzdem wieder auf Ausgangsniveau ab.
morchel
HIVC zum Vergleich sank nach eklatantem Anstieg trotzdem wieder auf Ausgangsniveau ab.
morchel
Hallo allerseits,
ein Häppchen aus dem RB...weiß jemand wie groß die erwähnte Zeitung ist???NEW YORK NEWSDAY NEWS!!!!!!!!!!
Old Drug, New Hope
Used in WWII, immune-system booster is now tested in AIDS fight
by Jamie Talan
Staff Writer
AN EXPERIMENTAL MEDICINE injected into U.S. military men during World War II fell into obscurity for decades and now has re-emerged in the battle against AIDS.
The drug-Substance R or Reticulose- stimulates the immune system and also interferes with viral replication, making it an important advance in pharmacology, doctors say. After more than 60 years of use, the drug is finally undergoing testing to move it through the Food and Drug Administration process.
Meanwhile, people such as Octavio A. Perez, a 32-year-old AIDS patient in Manhattan, report substantial benefit through the current drug trials. Perez spent years on a mix of AIDS drugs that caused such troublesome side effects-distressing nightmares and neuropathies of the hands and legs-that they kept him housebound. Two months ago, he began taking injections of Reticulose.
"It`s really been unbelievable," said Perez. "I can walk without pain. I can sleep again." It is too early to tell whether Substance R will become a mainstream, federally approved drug for AIDS, or for any of the other conditions that might benefit from enhancing the immune system. But a small pharmaceutical company called Advanced Viral Research Corp. is betting on the drug`s 67-year-old anecdotal history and has begun testing it in AIDS patients overseas. The company is planning to file several applications for its use with the Food and Drug Administration, which means that testing could move forward.
Whether the drug proves as powerful as the developers` claim, the substance stands as a lesson in endurance. Substance R was created in 1933 by a doctor who wanted to develop a medicine for his patients that would mimic the body`s immune system. What Dr. Vincent Lapenta didn`t know-and what no one would know for more than 60 years-is that the compound fits into a relatively new class of drugs called protein nucleic acids.
"I had never known anything to do this," said Dr. Shalom Z. Hirschman, former director of infectious diseases at Mount Sinai School of Medicine, who has left his tenured position to develop and test Reticulose.
"The lure of opening up an entire new field of therapeutics was too much," Hirschman said.
It will take years of testing before the FDA has enough data to rule on a drug`s effectiveness and grant approval for use in the United States.
Ironically, Reticulose had a place in medicine for decades, listed in the Physician`s Desk Reference from 1940 to 1960. At the time, Phillips Roxanne Pharmaceutical Co. was manufacturing the drug for Lapenta. In the early `60s, the company sold rights of the drug to Key Pharmaceuticals.
Then, it disappeared from the PDR.
Scientists at Key Pharmaceuticals were having difficulty figuring out the chemistry of the drug-how it works-in an attempt to comply with new FDA guidelines on drug regulation passed in 1962. Scientists at Phillips Roxanne had made a slight change in the formula in 1959-bovine serum replaced horse serum as a stabilizing compound-and the newly created FDA would not allow the drug to bypass the regulation process as it had done with thousands of other drugs developed before the federal law went into effect. (The change was necessary because horse serum was linked to serum sickness.) Reticulose, now owned by Key, would have to be tested as a new drug.
Perplexed by its chemistry, the company abandoned the drug, selling rights to the substance to a Singapore firm. Within a few years, the overseas company began bankruptcy proceedings, and chances that Substance R would ever see the light of day seemed bleak.
But Bernard Friedland, a chemist at Key, would not give up on the drug.
He`d heard about the bankruptcy proceedings that began in 1972 and ended in 1985. He decided to buy the drug around 1985, and a manufacturing plant in the Bahamas that had been sitting in moth balls for more than a decade.
"I felt the drug was too important to lose," said Friedland, now 74. "I couldn`t let it die." The mixture created by Lapenta in 1933 was a brew of genetic RNA material and proteins grown at certain temperatures. He used the substance on his own patients for viral infections. Others also talked about its benefits. But like all drugs of its time, the clinical success was anecdotal. There was never a serious drug trial.
When the FDA threatened its availability in the early `60s, doctors began to hoard the injectable drug for their patients. Hundreds of thousands of patients were treated for influenza A, encephalitis and other viruses during the pre-FDA decades, Friedland said.
Col. Ralph Thompson, a physician of the U.S. Medical Corps and deputy director of the Armed Forces Institute of Pathology in Washington, D.C., witnessed the same benefits in some of his charges during World War II and later: "I shall never forget the miraculous course that followed the treatment with this drug," he told colleagues at a 1960 meeting. " ... and will remember those others of my command who became ill and stricken with influenza who did not receive Reticulose therapy." He said he had also recommended its use in children with virulent encephalitis.
The substance was still a chemical mystery to Friedland when he bought the drug from the bankruptcy courts. In 1995, Hirschman was asked to take a look at the drug. Hirschman had studied nucleic acids at the National Institutes of Health in the `60s, and he had just been reading a study on nucleic acids in Science when it hit him.
"I was looking at a peptide nucleic acid, a relatively new class of substances that have powerful effects on the inflammatory process," Hirschman said. Peptide nucleic acids were first described in the early `90s. "No one would have appreciated this chemistry," Hirschman said of the early developers of the drug.
The first person he called was Friedland, who had set up a company to work on Substance R.
Hirschman`s wife, Frances E. Newmann-Hirschman, a geneticist and AIDS crisis worker in Westchester, had been given samples of the drug to test. She`d been trying to find substances to fight AIDS, and she learned about Reticulose.
Her husband took the formula back to his lab. "I immediately began experimenting with it," he said. He discovered that the drug had potent interactions with the immune system, stimulating cytokines, interferon, tumor necrosis factor and other immune substances.
In addition to AIDS, the researchers believe it can also be a treatment for genital warts, human papillomavirus, herpes C virus and certain forms of arthritis. Hirschman said it could even help boost the immune system in cancer patients, a possibility that was first described by Thompson in 1960.
There are probably thousands of drugs in development that never make it into the hands of patients. But the protein nucleic acids are a new entity, opening up the possibilities of strengthening the immune system in its fight against infections, said Howard Young, section head of cellular and molecular immunology at the National Cancer Institute. He`s done some genetic laboratory work with Reticulose. "There`s a reasonable basis for it to work. A lot of people are studying this new class of drugs for their potential to modulate the immune system." In 1996, Hirschman`s company launched the first rigorous double-blind control trials of Reticulose.
In the study, 43 AIDS patients in Barbados were randomized to receive Reticulose or a placebo injection for 60 days. This was the only treatment these patients received. At the end of the study, patients who received the drug had no signs of opportunistic infections and reported feeling more energetic, Hirschman said. Those on placebo did not report similar benefits.
Nine of the patients are still on the drug, which is taken by injection every day.
Hirschman hopes that Reticulose might be used in conjunction with conventional AIDS cocktails to strengthen the immune system.
"The more we learn about this class of drugs, the better we will be able to tailor them to treat specific diseases," Hirschman said.
Gruß und beste Kurse
EE
ein Häppchen aus dem RB...weiß jemand wie groß die erwähnte Zeitung ist???NEW YORK NEWSDAY NEWS!!!!!!!!!!
Old Drug, New Hope
Used in WWII, immune-system booster is now tested in AIDS fight
by Jamie Talan
Staff Writer
AN EXPERIMENTAL MEDICINE injected into U.S. military men during World War II fell into obscurity for decades and now has re-emerged in the battle against AIDS.
The drug-Substance R or Reticulose- stimulates the immune system and also interferes with viral replication, making it an important advance in pharmacology, doctors say. After more than 60 years of use, the drug is finally undergoing testing to move it through the Food and Drug Administration process.
Meanwhile, people such as Octavio A. Perez, a 32-year-old AIDS patient in Manhattan, report substantial benefit through the current drug trials. Perez spent years on a mix of AIDS drugs that caused such troublesome side effects-distressing nightmares and neuropathies of the hands and legs-that they kept him housebound. Two months ago, he began taking injections of Reticulose.
"It`s really been unbelievable," said Perez. "I can walk without pain. I can sleep again." It is too early to tell whether Substance R will become a mainstream, federally approved drug for AIDS, or for any of the other conditions that might benefit from enhancing the immune system. But a small pharmaceutical company called Advanced Viral Research Corp. is betting on the drug`s 67-year-old anecdotal history and has begun testing it in AIDS patients overseas. The company is planning to file several applications for its use with the Food and Drug Administration, which means that testing could move forward.
Whether the drug proves as powerful as the developers` claim, the substance stands as a lesson in endurance. Substance R was created in 1933 by a doctor who wanted to develop a medicine for his patients that would mimic the body`s immune system. What Dr. Vincent Lapenta didn`t know-and what no one would know for more than 60 years-is that the compound fits into a relatively new class of drugs called protein nucleic acids.
"I had never known anything to do this," said Dr. Shalom Z. Hirschman, former director of infectious diseases at Mount Sinai School of Medicine, who has left his tenured position to develop and test Reticulose.
"The lure of opening up an entire new field of therapeutics was too much," Hirschman said.
It will take years of testing before the FDA has enough data to rule on a drug`s effectiveness and grant approval for use in the United States.
Ironically, Reticulose had a place in medicine for decades, listed in the Physician`s Desk Reference from 1940 to 1960. At the time, Phillips Roxanne Pharmaceutical Co. was manufacturing the drug for Lapenta. In the early `60s, the company sold rights of the drug to Key Pharmaceuticals.
Then, it disappeared from the PDR.
Scientists at Key Pharmaceuticals were having difficulty figuring out the chemistry of the drug-how it works-in an attempt to comply with new FDA guidelines on drug regulation passed in 1962. Scientists at Phillips Roxanne had made a slight change in the formula in 1959-bovine serum replaced horse serum as a stabilizing compound-and the newly created FDA would not allow the drug to bypass the regulation process as it had done with thousands of other drugs developed before the federal law went into effect. (The change was necessary because horse serum was linked to serum sickness.) Reticulose, now owned by Key, would have to be tested as a new drug.
Perplexed by its chemistry, the company abandoned the drug, selling rights to the substance to a Singapore firm. Within a few years, the overseas company began bankruptcy proceedings, and chances that Substance R would ever see the light of day seemed bleak.
But Bernard Friedland, a chemist at Key, would not give up on the drug.
He`d heard about the bankruptcy proceedings that began in 1972 and ended in 1985. He decided to buy the drug around 1985, and a manufacturing plant in the Bahamas that had been sitting in moth balls for more than a decade.
"I felt the drug was too important to lose," said Friedland, now 74. "I couldn`t let it die." The mixture created by Lapenta in 1933 was a brew of genetic RNA material and proteins grown at certain temperatures. He used the substance on his own patients for viral infections. Others also talked about its benefits. But like all drugs of its time, the clinical success was anecdotal. There was never a serious drug trial.
When the FDA threatened its availability in the early `60s, doctors began to hoard the injectable drug for their patients. Hundreds of thousands of patients were treated for influenza A, encephalitis and other viruses during the pre-FDA decades, Friedland said.
Col. Ralph Thompson, a physician of the U.S. Medical Corps and deputy director of the Armed Forces Institute of Pathology in Washington, D.C., witnessed the same benefits in some of his charges during World War II and later: "I shall never forget the miraculous course that followed the treatment with this drug," he told colleagues at a 1960 meeting. " ... and will remember those others of my command who became ill and stricken with influenza who did not receive Reticulose therapy." He said he had also recommended its use in children with virulent encephalitis.
The substance was still a chemical mystery to Friedland when he bought the drug from the bankruptcy courts. In 1995, Hirschman was asked to take a look at the drug. Hirschman had studied nucleic acids at the National Institutes of Health in the `60s, and he had just been reading a study on nucleic acids in Science when it hit him.
"I was looking at a peptide nucleic acid, a relatively new class of substances that have powerful effects on the inflammatory process," Hirschman said. Peptide nucleic acids were first described in the early `90s. "No one would have appreciated this chemistry," Hirschman said of the early developers of the drug.
The first person he called was Friedland, who had set up a company to work on Substance R.
Hirschman`s wife, Frances E. Newmann-Hirschman, a geneticist and AIDS crisis worker in Westchester, had been given samples of the drug to test. She`d been trying to find substances to fight AIDS, and she learned about Reticulose.
Her husband took the formula back to his lab. "I immediately began experimenting with it," he said. He discovered that the drug had potent interactions with the immune system, stimulating cytokines, interferon, tumor necrosis factor and other immune substances.
In addition to AIDS, the researchers believe it can also be a treatment for genital warts, human papillomavirus, herpes C virus and certain forms of arthritis. Hirschman said it could even help boost the immune system in cancer patients, a possibility that was first described by Thompson in 1960.
There are probably thousands of drugs in development that never make it into the hands of patients. But the protein nucleic acids are a new entity, opening up the possibilities of strengthening the immune system in its fight against infections, said Howard Young, section head of cellular and molecular immunology at the National Cancer Institute. He`s done some genetic laboratory work with Reticulose. "There`s a reasonable basis for it to work. A lot of people are studying this new class of drugs for their potential to modulate the immune system." In 1996, Hirschman`s company launched the first rigorous double-blind control trials of Reticulose.
In the study, 43 AIDS patients in Barbados were randomized to receive Reticulose or a placebo injection for 60 days. This was the only treatment these patients received. At the end of the study, patients who received the drug had no signs of opportunistic infections and reported feeling more energetic, Hirschman said. Those on placebo did not report similar benefits.
Nine of the patients are still on the drug, which is taken by injection every day.
Hirschman hopes that Reticulose might be used in conjunction with conventional AIDS cocktails to strengthen the immune system.
"The more we learn about this class of drugs, the better we will be able to tailor them to treat specific diseases," Hirschman said.
Gruß und beste Kurse
EE
Great post!
Wenn der Kurs auf 25$ steigen würde, wär ich ATS Millionär!
hope so!
morchel
Wenn der Kurs auf 25$ steigen würde, wär ich ATS Millionär!
hope so!
morchel
Trading Spotlight
Dieser Artikel bestaetigt mich in meiner positiven Meinung zu ADVR, nur leider geht der Kurs runter.
Good luck
Glurac
Good luck
Glurac
Hab ich gerade bei Yahoo gefunden:
--------------------------------------------------------------------------------
Related Quotes
ADVR.OB
0.490000
-0.020000
delayed 20 mins - disclaimer
Wednesday July 12, 11:53 am Eastern Time
Company Press Release
Advanced Viral Research Corp. Triples Size of Research and Development Facilities
City of Yonkers to Hold Press Conference on Wednesday, July 12 at 2:00 PM ET
YONKERS, N.Y.--(BUSINESS WIRE)--July 12, 2000--Advanced Viral Research Corp. (OTCBB:ADVR - news) today announced that the City of Yonkers will hold a press conference later today to celebrate the completed expansion of Advanced Viral Research Corp.`s research and development facilities.
Mayor John D. Spencer is expected to attend the event, along with distinguished members of the City of Yonkers, the Yonkers Chamber of Commerce, the Westchester County Executives Office, Congresswoman Nita Lowey and Congressman Eliot Engel`s offices, and the Empire State Development Corporation. The invitation-only event will be held at Advanced Viral Research Corp. headquarters, 200 Corporate Boulevard South, Yonkers, NY at 2:00 PM ET.
The announcement of the expansion comes on the heels of a feature story in the July 11, 2000 issue of NEWSDAY, the nation`s eighth largest daily newspaper, about the biopharmaceutical firm and its exciting research on the treatment of AIDS and other diseases.
The expansion, which increases the facility to more than 18,000 square feet, triples the company`s existing space at their Yonkers headquarters. The new space will house The Advanced Viral Research Institute, which the company created to foster individual scientific inquiry and creativity. In addition to enlarging its facility, Advanced Viral Research Corp. also plans to expand its staffing thanks in part to a grant from the Empire State Development Corporation for the creation of new jobs.
``We are confident that the expansion of Advanced Viral Research Corp. will increase employment opportunities and further stimulate economic development in our city,`` noted Mayor Spencer. ``This is exactly the type of high quality, reputable organization that we are proud to have as a staple of our business community.``
Advanced Viral Research Corp.`s flagship drug, Product R, is a non-toxic peptide nucleic acid (PNA) immunomodulator being developed by the company as a broad-spectrum antiviral drug. Product R shows promise for the treatment of viral infections such as AIDS and Human Papilloma Virus (HPV), and autoimmune diseases like rheumatoid arthritis.
``We are thrilled to call Yonkers our home, and hope to serve as a model for other companies looking to do business in this wonderful region,`` said Shalom Z. Hirschman, MD, president and CEO of Advanced Viral Research Corp. ``We are on a mission to make great advances in the treatment of AIDS and other devastating diseases, and look forward to the continued support of the Mayor, the City of Yonkers, the County Executive`s Office, Congresswoman Lowey, Congressman Engel, and our friends at the Chamber of Commerce.``
At The Advanced Viral Research Institute, a respected team of molecular biologists, immunologists and other scientists conduct biomedical research in an academically oriented environment. Recent successes include identifying Product R`s mechanism of action, which will help with the company`s planned Investigational New Drug (IND) application to the FDA. The Advanced Viral Research Institute also is developing other PNA-based therapeutics.
Advanced Viral Research Corp. laboratory studies have shown that Product R inhibits the production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for the human immunodeficiency virus (HIV).
Research by scientists at The Advanced Viral Research Institute has also shown that Product R interferes with the expression of a key protein implicated in the development of cervical cancer (the product of the E7 gene of HPV subtype 18). Moreover, recent research has demonstrated that Product R interferes with the actual replication and growth of HPV in cell culture. These results indicate that Product R may be useful in the treatment of disseminated HPV infection and may interfere with the development of cervical cancer.
Preliminary clinical results suggest that Product R may be an effective non-toxic drug for both systemic and topical therapy of disseminated HPV infection in people with AIDS.
About Advanced Viral Research Corp.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Product R, is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.
--------------------------------------------------------------------------------
Contact:
Mike Rosen
--------------------------------------------------------------------------------
Related Quotes
ADVR.OB
0.490000
-0.020000
delayed 20 mins - disclaimer
Wednesday July 12, 11:53 am Eastern Time
Company Press Release
Advanced Viral Research Corp. Triples Size of Research and Development Facilities
City of Yonkers to Hold Press Conference on Wednesday, July 12 at 2:00 PM ET
YONKERS, N.Y.--(BUSINESS WIRE)--July 12, 2000--Advanced Viral Research Corp. (OTCBB:ADVR - news) today announced that the City of Yonkers will hold a press conference later today to celebrate the completed expansion of Advanced Viral Research Corp.`s research and development facilities.
Mayor John D. Spencer is expected to attend the event, along with distinguished members of the City of Yonkers, the Yonkers Chamber of Commerce, the Westchester County Executives Office, Congresswoman Nita Lowey and Congressman Eliot Engel`s offices, and the Empire State Development Corporation. The invitation-only event will be held at Advanced Viral Research Corp. headquarters, 200 Corporate Boulevard South, Yonkers, NY at 2:00 PM ET.
The announcement of the expansion comes on the heels of a feature story in the July 11, 2000 issue of NEWSDAY, the nation`s eighth largest daily newspaper, about the biopharmaceutical firm and its exciting research on the treatment of AIDS and other diseases.
The expansion, which increases the facility to more than 18,000 square feet, triples the company`s existing space at their Yonkers headquarters. The new space will house The Advanced Viral Research Institute, which the company created to foster individual scientific inquiry and creativity. In addition to enlarging its facility, Advanced Viral Research Corp. also plans to expand its staffing thanks in part to a grant from the Empire State Development Corporation for the creation of new jobs.
``We are confident that the expansion of Advanced Viral Research Corp. will increase employment opportunities and further stimulate economic development in our city,`` noted Mayor Spencer. ``This is exactly the type of high quality, reputable organization that we are proud to have as a staple of our business community.``
Advanced Viral Research Corp.`s flagship drug, Product R, is a non-toxic peptide nucleic acid (PNA) immunomodulator being developed by the company as a broad-spectrum antiviral drug. Product R shows promise for the treatment of viral infections such as AIDS and Human Papilloma Virus (HPV), and autoimmune diseases like rheumatoid arthritis.
``We are thrilled to call Yonkers our home, and hope to serve as a model for other companies looking to do business in this wonderful region,`` said Shalom Z. Hirschman, MD, president and CEO of Advanced Viral Research Corp. ``We are on a mission to make great advances in the treatment of AIDS and other devastating diseases, and look forward to the continued support of the Mayor, the City of Yonkers, the County Executive`s Office, Congresswoman Lowey, Congressman Engel, and our friends at the Chamber of Commerce.``
At The Advanced Viral Research Institute, a respected team of molecular biologists, immunologists and other scientists conduct biomedical research in an academically oriented environment. Recent successes include identifying Product R`s mechanism of action, which will help with the company`s planned Investigational New Drug (IND) application to the FDA. The Advanced Viral Research Institute also is developing other PNA-based therapeutics.
Advanced Viral Research Corp. laboratory studies have shown that Product R inhibits the production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for the human immunodeficiency virus (HIV).
Research by scientists at The Advanced Viral Research Institute has also shown that Product R interferes with the expression of a key protein implicated in the development of cervical cancer (the product of the E7 gene of HPV subtype 18). Moreover, recent research has demonstrated that Product R interferes with the actual replication and growth of HPV in cell culture. These results indicate that Product R may be useful in the treatment of disseminated HPV infection and may interfere with the development of cervical cancer.
Preliminary clinical results suggest that Product R may be an effective non-toxic drug for both systemic and topical therapy of disseminated HPV infection in people with AIDS.
About Advanced Viral Research Corp.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Product R, is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.
--------------------------------------------------------------------------------
Contact:
Mike Rosen
grad wollt ich es posten .....
z.D.
ADVR vergrößert das Labor auf die dreifache Größe. Personal soll auch aufgenommen werden! Die rechnen anscheinend mit viel Arbeit in der nächsten Zeit!
Sogar der Bürgermeister von Yonkers, Spencer, scheint hocherfreut! :-)
...und schon kratzt der Kurs wieder an der 60C Marke!
...ooops...schon darüber....das geht aber schnell!
Tip für Leute die viele Aktien gleichzeitig verfolgen wollen (speziell Nasdaq und OTC) sind mit dem Medved Quotetracker sehr gut beraten.Er hat viele Features die alle aufzuzählen den Rahmen sprengen würde.(Historic charts, News Research, Level 2, viele vorkonfigurierte Server, aktuelle bids und asks, uvm) downloadlink auf meiner Seite http://www.8ung.at/zockstocks
z.D.
ADVR vergrößert das Labor auf die dreifache Größe. Personal soll auch aufgenommen werden! Die rechnen anscheinend mit viel Arbeit in der nächsten Zeit!
Sogar der Bürgermeister von Yonkers, Spencer, scheint hocherfreut! :-)
...und schon kratzt der Kurs wieder an der 60C Marke!
...ooops...schon darüber....das geht aber schnell!
Tip für Leute die viele Aktien gleichzeitig verfolgen wollen (speziell Nasdaq und OTC) sind mit dem Medved Quotetracker sehr gut beraten.Er hat viele Features die alle aufzuzählen den Rahmen sprengen würde.(Historic charts, News Research, Level 2, viele vorkonfigurierte Server, aktuelle bids und asks, uvm) downloadlink auf meiner Seite http://www.8ung.at/zockstocks
Hi Leute,
interessantes Post...
I saw this news on the site http://america-invest.stockpoint.com/america-invest/NewsStor…
pennyPI.com To Tour 1,000 Of The Top OTCBB, Pink Sheet, And Nasdaq-SC Companies
RIDGELAND, MS, Jul 19, 2000 (INTERNET WIRE via COMTEX) -- pennyPI.com, Inc.
(PPI) is pleased to announce the start of its new "Corporate Tour 1,000"
campaign. "Corporate Tour 1,000" is an aggressive campaign to obtain "on-site"
video documentation of certain company facilities, management, and operations.
pennyPI.com`s near-term goal is to obtain video tours of the top 1,000 OTCBB,
Pink Sheet, and NasdaqSC companies, such as:
Advanced Viral Research Corporation (OTCBB: ADVR) Thermo Tech Technologies, Inc.
(OTCBB: TTRIF) WSi Interactive Corporation (OTCBB: WIZZF) HemaSure, Inc. (OTCBB:
HMSR) Clancey Systems International, Inc. (OTCBB: CLSI) Enterprise Solutions,
Inc. (OTC: EPSO) Integral Technologies, Inc. (OTCBB: ITKG) Value Holdings, Inc.
(OTCBB: VALH) Magnitude Information Systems, Inc. (OTCBB: MAGY) Equalnet
Communications Corporation (OTCBB: ENET)
These video tours have standard guidelines and will be conducted by trained
professionals. The videos will be forwarded to PPI`s production facility
allowing pennyPI.com to provide professionally produced streaming video tours of
small and microcap company operations via the PPI website:
www.pennypi.com. staff has begun contacting selected companies in an attempt to
schedule these "video-visits", which will be an unbiased virtual tour to
document critical facets of a company`s business such as: Physical location;
Management/Staff; Production Facilities/Processes; Distribution
Facilities/Process; etc. pennyPI.com is dedicated to touring any company
location within North America, at no cost to the companies themselves.
pennyPI.com accepts no compensation from companies its "covers" thereby
maintaining a complete independent and unbiased position.
INVESTOR INTERACTION
pennyPI.com is asking all shareholders of OTCBB, Pink Sheet, and Nasdaq-SC
companies to visit a special pennyPI.com web page to register support on a
"per-company" basis of this large "tour" endeavor:
www.pennypi.com/toursupport/toursupport.htm light of recent fraud cases
announced by the SEC, US Attorney, and FBI; investors are becoming more aware of
the importance of quality, unbiased research. pennyPI.com was founded on this
basis and believes the best evaluation of a company is through its history and a
hands-on tour of the company`s operations. The "Corporate Tour 1,000" campaign
will provide investors with this hands-on view.
COMPANY INTERACTION
Any OTCBB, Pink Sheet, or Nasdaq-SC company may contact pennyPI.com for
information about scheduling a free Corporate Tour by sending an email to:
tour@pennypi.com.
pennyPI.com is the first unbiased resource for penny stock and alternate
investing. pennyPI.com is a privately owned Mississippi based Internet startup:
www.pennypi.com. The site offers independent, unbiased information on more than
6,600 penny stocks trading on the OTCBB and "Pink Sheets". As a policy of
complete independence, pennyPI.com doesn`t accept any compensation from
non-listed companies nor does it hold positions in non-listed securities.
pennyPI.com has absolutely no affiliations with any company mentioned herein.
For more information regarding pennyPI.com please visit our web site
www.pennypi.com or email us at info@pennypi.com, or call (601) 978-3399.
CONTACT: Brian Welcher
601-978-3399
Hi Morchel,
ich hoffe ich darf Dich nochmal wegen dem genialen Medved belästigen...
1. Gebe ich Ciscoin das Portfolio ein, dann kommt nix, bei CMGI gehts
2. Die Pink sheets, muß da auch ein Zusat wie OB dran oder muß ich da nur die Serverquelle wechseln um Daten zu kriegen?
3. Wie kann ich meinen Kaufpreis und die Menge der Aktien angene um den aktuellen Stand zu haben?
4. Kann ich auch kanadisache und deutsche Aktien eingeben?
Danke im voraus für die Hilfe
Gruß und beste Kurse
EE
PS Dein Kursziel für ADVR (auf 8ung) ist ziemlich heftig, haben die noch mehr Produkte in der Pipeline?
interessantes Post...
I saw this news on the site http://america-invest.stockpoint.com/america-invest/NewsStor…
pennyPI.com To Tour 1,000 Of The Top OTCBB, Pink Sheet, And Nasdaq-SC Companies
RIDGELAND, MS, Jul 19, 2000 (INTERNET WIRE via COMTEX) -- pennyPI.com, Inc.
(PPI) is pleased to announce the start of its new "Corporate Tour 1,000"
campaign. "Corporate Tour 1,000" is an aggressive campaign to obtain "on-site"
video documentation of certain company facilities, management, and operations.
pennyPI.com`s near-term goal is to obtain video tours of the top 1,000 OTCBB,
Pink Sheet, and NasdaqSC companies, such as:
Advanced Viral Research Corporation (OTCBB: ADVR) Thermo Tech Technologies, Inc.
(OTCBB: TTRIF) WSi Interactive Corporation (OTCBB: WIZZF) HemaSure, Inc. (OTCBB:
HMSR) Clancey Systems International, Inc. (OTCBB: CLSI) Enterprise Solutions,
Inc. (OTC: EPSO) Integral Technologies, Inc. (OTCBB: ITKG) Value Holdings, Inc.
(OTCBB: VALH) Magnitude Information Systems, Inc. (OTCBB: MAGY) Equalnet
Communications Corporation (OTCBB: ENET)
These video tours have standard guidelines and will be conducted by trained
professionals. The videos will be forwarded to PPI`s production facility
allowing pennyPI.com to provide professionally produced streaming video tours of
small and microcap company operations via the PPI website:
www.pennypi.com. staff has begun contacting selected companies in an attempt to
schedule these "video-visits", which will be an unbiased virtual tour to
document critical facets of a company`s business such as: Physical location;
Management/Staff; Production Facilities/Processes; Distribution
Facilities/Process; etc. pennyPI.com is dedicated to touring any company
location within North America, at no cost to the companies themselves.
pennyPI.com accepts no compensation from companies its "covers" thereby
maintaining a complete independent and unbiased position.
INVESTOR INTERACTION
pennyPI.com is asking all shareholders of OTCBB, Pink Sheet, and Nasdaq-SC
companies to visit a special pennyPI.com web page to register support on a
"per-company" basis of this large "tour" endeavor:
www.pennypi.com/toursupport/toursupport.htm light of recent fraud cases
announced by the SEC, US Attorney, and FBI; investors are becoming more aware of
the importance of quality, unbiased research. pennyPI.com was founded on this
basis and believes the best evaluation of a company is through its history and a
hands-on tour of the company`s operations. The "Corporate Tour 1,000" campaign
will provide investors with this hands-on view.
COMPANY INTERACTION
Any OTCBB, Pink Sheet, or Nasdaq-SC company may contact pennyPI.com for
information about scheduling a free Corporate Tour by sending an email to:
tour@pennypi.com.
pennyPI.com is the first unbiased resource for penny stock and alternate
investing. pennyPI.com is a privately owned Mississippi based Internet startup:
www.pennypi.com. The site offers independent, unbiased information on more than
6,600 penny stocks trading on the OTCBB and "Pink Sheets". As a policy of
complete independence, pennyPI.com doesn`t accept any compensation from
non-listed companies nor does it hold positions in non-listed securities.
pennyPI.com has absolutely no affiliations with any company mentioned herein.
For more information regarding pennyPI.com please visit our web site
www.pennypi.com or email us at info@pennypi.com, or call (601) 978-3399.
CONTACT: Brian Welcher
601-978-3399
Hi Morchel,
ich hoffe ich darf Dich nochmal wegen dem genialen Medved belästigen...
1. Gebe ich Ciscoin das Portfolio ein, dann kommt nix, bei CMGI gehts
2. Die Pink sheets, muß da auch ein Zusat wie OB dran oder muß ich da nur die Serverquelle wechseln um Daten zu kriegen?
3. Wie kann ich meinen Kaufpreis und die Menge der Aktien angene um den aktuellen Stand zu haben?
4. Kann ich auch kanadisache und deutsche Aktien eingeben?
Danke im voraus für die Hilfe
Gruß und beste Kurse
EE
PS Dein Kursziel für ADVR (auf 8ung) ist ziemlich heftig, haben die noch mehr Produkte in der Pipeline?
Wenn du den Yahoo server benutzt mußt du für OTC Aktien immer ein .OB anhängen. für Nasdaq genügt das Kurzzeichen alleine.
Pinkshhets bekommst du über Yahoo nicht.
Willst du die gesamte palette, dann nimm dir den Server von PCQuote.com. Da brauchst du nur das Kurzzeichen eingeben.(ohne ob oder dergl.)
Kaufpreis und Menge gibst du ein indem du auf Portfolio klickst.
Wähle Edit Portfolio/Alerts
Dann wähle dein Portfolio aus
Quantity: gibst du die Stück ein
Base Price: zu welchen Preis du gekauft hast
Commission: Spesen (am besten rechnest du gleich verkaufsspesen mit ein)
Achtung! beim Quotetracker mußt du statt einem Komma einen Punkt eingeben. Also 0.365 $
außerdem kannst du von Fractional (Bruch) auf dezimal umstellen :
Unter Options --> Misc
happy trading
morchel
PS: vergiß nicht das bei ADVR das Produkt "R" noch gegen andere Krankheiten hilft. Wer weiß was da noch alles dazukommt.
Pinkshhets bekommst du über Yahoo nicht.
Willst du die gesamte palette, dann nimm dir den Server von PCQuote.com. Da brauchst du nur das Kurzzeichen eingeben.(ohne ob oder dergl.)
Kaufpreis und Menge gibst du ein indem du auf Portfolio klickst.
Wähle Edit Portfolio/Alerts
Dann wähle dein Portfolio aus
Quantity: gibst du die Stück ein
Base Price: zu welchen Preis du gekauft hast
Commission: Spesen (am besten rechnest du gleich verkaufsspesen mit ein)
Achtung! beim Quotetracker mußt du statt einem Komma einen Punkt eingeben. Also 0.365 $
außerdem kannst du von Fractional (Bruch) auf dezimal umstellen :
Unter Options --> Misc
happy trading
morchel
PS: vergiß nicht das bei ADVR das Produkt "R" noch gegen andere Krankheiten hilft. Wer weiß was da noch alles dazukommt.
Product R, is a non-toxic peptide nucleic acid (PNA) immunomodulator being developed by the company as a broad-spectrum antiviral drug. Product R shows promise for the treatment of viral infections such as AIDS and Human Papilloma Virus (HPV), and autoimmune diseases like rheumatoid arthritis.
Aids, Papilloma virus, Rheumatische Arthritis und wer weiß noch, was alles dazukommt!
(Siehe Pfitzer)
http://www.8ung.at/zockstocks
morchel
Aids, Papilloma virus, Rheumatische Arthritis und wer weiß noch, was alles dazukommt!
(Siehe Pfitzer)
http://www.8ung.at/zockstocks
morchel
AIDS Treatment Activists Call for Fast Track Development of Reticulose
NEW YORK, Jul 26, 2000 /PRNewswire via COMTEX/ -- With the close of the 13th
International AIDS Conference, a coalition of leading AIDS Treatment activists
are demanding better access to Reticulose, a lipoprotein-nucleic acid complex
manufactured by Advanced Viral Research that has shown promise in the treatment
of many of the symptoms of HIV disease. Reticulose is presently available
through a compassionate use program approved by the FDA, but many activists are
claiming this is not enough.
"Many people presently receiving Reticulose through the compassionate access
program are doing better but there are hundreds of thousands of people living
with AIDS who need access to this promising therapy but can`t receive it," said
David Miller, Director of Brooklyn Medical Arts AIDS CARE Center and a member of
ACT UP Brooklyn. "We are urging Advanced Viral Research to peruse federal
clinical research and to apply for fast track designation at the FDA to
accelerate access for the thousands that are intolerant to the side effects of
antiviral therapy."
Jeannie Gibbs, a veteran AIDS treatment activist now working with the
International HIV IBT Working Group is petitioning FDA officials and legislators
to move aggressively to ensure access to Reticulose. "I`m confident we`re going
to secure the necessary support to encourage the development of Reticulose in
the next few weeks."
Advanced Viral Research is presently pursuing mature discussions with leading
clinical research organizations including Anderson Clinical Research Institute
who will be retained to execute trials in HIV patients during the next two to
three months.
Sources close to the company revealed that dramatic in vitro results of a study
analyzing the potential of Reticulose for the treatment of HIV will be submitted
for presentation during the 38th annual meeting of the Infectious Disease
Society of America taking place September 7-10, 2000 in New Orleans, LA.
SOURCE Brooklyn Medical Arts AIDS CARE Center
CONTACT: David Miller, 718-222-4600 or Jeannie Gibbs, both of Brooklyn
Medial Arts AIDS CARE Center
http://www.prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
NEW YORK, Jul 26, 2000 /PRNewswire via COMTEX/ -- With the close of the 13th
International AIDS Conference, a coalition of leading AIDS Treatment activists
are demanding better access to Reticulose, a lipoprotein-nucleic acid complex
manufactured by Advanced Viral Research that has shown promise in the treatment
of many of the symptoms of HIV disease. Reticulose is presently available
through a compassionate use program approved by the FDA, but many activists are
claiming this is not enough.
"Many people presently receiving Reticulose through the compassionate access
program are doing better but there are hundreds of thousands of people living
with AIDS who need access to this promising therapy but can`t receive it," said
David Miller, Director of Brooklyn Medical Arts AIDS CARE Center and a member of
ACT UP Brooklyn. "We are urging Advanced Viral Research to peruse federal
clinical research and to apply for fast track designation at the FDA to
accelerate access for the thousands that are intolerant to the side effects of
antiviral therapy."
Jeannie Gibbs, a veteran AIDS treatment activist now working with the
International HIV IBT Working Group is petitioning FDA officials and legislators
to move aggressively to ensure access to Reticulose. "I`m confident we`re going
to secure the necessary support to encourage the development of Reticulose in
the next few weeks."
Advanced Viral Research is presently pursuing mature discussions with leading
clinical research organizations including Anderson Clinical Research Institute
who will be retained to execute trials in HIV patients during the next two to
three months.
Sources close to the company revealed that dramatic in vitro results of a study
analyzing the potential of Reticulose for the treatment of HIV will be submitted
for presentation during the 38th annual meeting of the Infectious Disease
Society of America taking place September 7-10, 2000 in New Orleans, LA.
SOURCE Brooklyn Medical Arts AIDS CARE Center
CONTACT: David Miller, 718-222-4600 or Jeannie Gibbs, both of Brooklyn
Medial Arts AIDS CARE Center
http://www.prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
Yepp,
und schon zieht der Kurs in USA wieder an.
karo
und schon zieht der Kurs in USA wieder an.
karo
ein gutes dickes + steht vor der Prozentangabe von 11,11%
Im Bericht oberhalb war zu lesen eine Zeitangabe: "next weeks"
für mich noch immer ADVR ---> strong buy
morchel
Im Bericht oberhalb war zu lesen eine Zeitangabe: "next weeks"
für mich noch immer ADVR ---> strong buy
morchel
Nur ADVR und Respektive SPAZ scheint das ganze NASDAQ auf und ab nichts auszumachen!
In the nex few weeks!
(siehe Pressemitteilung oben)
morchel
In the nex few weeks!
(siehe Pressemitteilung oben)
morchel
hi Morchel,
arg still geworden um ADVR, was meinst Du zu den Anküdigungen? Waren doch keine ergreifenden News bisher dabei?!
Der tägliche Umsatz ist sehr hoch, der Kurs dümpelt, ich werde da nicht schlau draus. Hast Du dir schon mal die Insidertrades von ADVR angeschaut???
Dieses Jahr nur!!! Verkäufe. Wie gesagt ich werde aus dem ganzen nicht schlau...
Schaun mr mal
Gruß und beste Kurse
EE
PS KZ immer noch 20$?
arg still geworden um ADVR, was meinst Du zu den Anküdigungen? Waren doch keine ergreifenden News bisher dabei?!
Der tägliche Umsatz ist sehr hoch, der Kurs dümpelt, ich werde da nicht schlau draus. Hast Du dir schon mal die Insidertrades von ADVR angeschaut???
Dieses Jahr nur!!! Verkäufe. Wie gesagt ich werde aus dem ganzen nicht schlau...
Schaun mr mal
Gruß und beste Kurse
EE
PS KZ immer noch 20$?
Stille ist an der OTC normalerweise tölich! Dafür hält sich ADVR ziemlich gut. Seit dem Tief (ca 0,3 nach dem Zacken im März) hat ADVR doch ca 80% zugelegt! In den letzten Tagen zeigt sie sich besonders stark. Mit guten Umsätzen und zur Tendenz über 0,5!
Bedenke: Wenn sich eine Firma jahrelang nur mit einem Thema auseinandersetzt, wie ADVR mit dem Präparat "R", da muss doch was dahinter sein, denn sonst würden die Forschungen, die bestimmt nicht billig sind, schon längst abgebrochen sein.(Ich glaube "R" hatte die erste Erwähnung 96 oder 97) Das wird jetzt durchgezogen!
Ich bin noch immer zuversichtlich!!!
morchel
Bedenke: Wenn sich eine Firma jahrelang nur mit einem Thema auseinandersetzt, wie ADVR mit dem Präparat "R", da muss doch was dahinter sein, denn sonst würden die Forschungen, die bestimmt nicht billig sind, schon längst abgebrochen sein.(Ich glaube "R" hatte die erste Erwähnung 96 oder 97) Das wird jetzt durchgezogen!
Ich bin noch immer zuversichtlich!!!
morchel
Interessanter Vergleich!
Amazing! ADVR vs IMNX!
I`ve always compared ADVR to IMNX and now it`s independently confirmed!
Immunex (IMNX) comparison is a strong parallel that is enlightening on the long-term possibilities of ADVR.:
Immunex (IMNX)
Shares outstanding 500.6 million (IMNX)
Market capitalization $23.4 billion
Share price (July 28, 2000) 46 3/4
52 week high 83 3/16
Share price (July 29, 1996) split-adjusted .96 cents/share
Product concentration 78% of sales from Enbrel (Rheumatoid Arthritis drug approved late last year)
IMNX closed today at $47 5/8. $24 Billion dollar Market cap!
With all the applications of Product R, ADVR has the potential of having a $100+ billion dollar market cap!
That would translate into a $300 stock price!
I guess $10 short term is not unrealistic!
Die Firmen sind ähnlich! Sollte sich das Produkt R so entwickeln wie es beabsichtigt ist würde es den Sharepreis in die 300$ Region heben! (Meinung das Posters auf dem RB Board)
Kurzfristig 10$ realistisch. (angeblich)
Tja, hoffen wir das Beste!!!
morchel
Amazing! ADVR vs IMNX!
I`ve always compared ADVR to IMNX and now it`s independently confirmed!
Immunex (IMNX) comparison is a strong parallel that is enlightening on the long-term possibilities of ADVR.:
Immunex (IMNX)
Shares outstanding 500.6 million (IMNX)
Market capitalization $23.4 billion
Share price (July 28, 2000) 46 3/4
52 week high 83 3/16
Share price (July 29, 1996) split-adjusted .96 cents/share
Product concentration 78% of sales from Enbrel (Rheumatoid Arthritis drug approved late last year)
IMNX closed today at $47 5/8. $24 Billion dollar Market cap!
With all the applications of Product R, ADVR has the potential of having a $100+ billion dollar market cap!
That would translate into a $300 stock price!
I guess $10 short term is not unrealistic!
Die Firmen sind ähnlich! Sollte sich das Produkt R so entwickeln wie es beabsichtigt ist würde es den Sharepreis in die 300$ Region heben! (Meinung das Posters auf dem RB Board)
Kurzfristig 10$ realistisch. (angeblich)
Tja, hoffen wir das Beste!!!
morchel
Hier habe ich etws über das Human Papiloma Virus gfunden! (War mir bis dato völlig unbekannt)Produkt "R" von ADVR soll auch dagengen helfen!
Cervical Cancer
What is it? Cervical cancer begins in the lining of the cervix, the lower part of the uterus which connects the womb, or uterus, to the vagina, or birth canal. When cervical cancer arises, the tumor can replace the normal cervix and can spread to the lymph nodes, bladder, rectum or other distant sites.
Symptoms: In its earliest stages, symptoms are few, which is why it is important to have annual Pap tests to detect abnormalities. In more advanced stages, signs may include vaginal discharge, abnormal bleeding and pain or bleeding following intercourse.
Risk factors: This year, nearly 13,000 women will be diagnosed with cervical cancer, and 4,600 will die from the disease. Cervical cancer is rare in women under age 15, but increases in the late teens to early thirties, then plateaus after 40. Certain behaviors increase the risk of cervical cancer. For example, infection with the human papilloma virus (HPV), which can be passed from one person to another during sex, is a leading risk factor. Having intercourse at an early age, with many partners, or with partners who have had many partners all contribute to cervical cancer risk. HIV infection weakens the immune system and also increases cervical cancer risk. Women who smoke are nearly twice as likely than non-smokers to get cervical cancer.
Detection and treatment: The Pap test is highly successful in identifying pre-invasive and early invasive cancers. Depending on the stage of the disease, surgery, radiation and chemotherapy are the main treatments. If detected in early stages, it may be possible to maintain the ability to conceive. In other cases, loss of fertility does not have to be compounded by early menopause.
Habe den Bericht etwas gekürzt! (währe sonst zu lange)
morchel
http://www.8ung.at/zockstocks" target="_blank" rel="nofollow ugc noopener">http://www.8ung.at/zockstocks
Cervical Cancer
What is it? Cervical cancer begins in the lining of the cervix, the lower part of the uterus which connects the womb, or uterus, to the vagina, or birth canal. When cervical cancer arises, the tumor can replace the normal cervix and can spread to the lymph nodes, bladder, rectum or other distant sites.
Symptoms: In its earliest stages, symptoms are few, which is why it is important to have annual Pap tests to detect abnormalities. In more advanced stages, signs may include vaginal discharge, abnormal bleeding and pain or bleeding following intercourse.
Risk factors: This year, nearly 13,000 women will be diagnosed with cervical cancer, and 4,600 will die from the disease. Cervical cancer is rare in women under age 15, but increases in the late teens to early thirties, then plateaus after 40. Certain behaviors increase the risk of cervical cancer. For example, infection with the human papilloma virus (HPV), which can be passed from one person to another during sex, is a leading risk factor. Having intercourse at an early age, with many partners, or with partners who have had many partners all contribute to cervical cancer risk. HIV infection weakens the immune system and also increases cervical cancer risk. Women who smoke are nearly twice as likely than non-smokers to get cervical cancer.
Detection and treatment: The Pap test is highly successful in identifying pre-invasive and early invasive cancers. Depending on the stage of the disease, surgery, radiation and chemotherapy are the main treatments. If detected in early stages, it may be possible to maintain the ability to conceive. In other cases, loss of fertility does not have to be compounded by early menopause.
Habe den Bericht etwas gekürzt! (währe sonst zu lange)
morchel
http://www.8ung.at/zockstocks" target="_blank" rel="nofollow ugc noopener">http://www.8ung.at/zockstocks
Tja wenn Produkt "R" wirklich so wirkungsvoll ist, dann müsste sich dies auch bald mal in handfesten News niederschlagen, sprich Beteiligungen, Zulassungsanträge ect.
Bin verhalten optimistisch...
Aber der Chart "schleicht" langsam wieder gen Norden, bei relativ hohen Umsätzen. Jedenfalls ist noch eine Menge Phantasie in dem Produkt "R" und somit in der Aktie.
karo
Bin verhalten optimistisch...
Aber der Chart "schleicht" langsam wieder gen Norden, bei relativ hohen Umsätzen. Jedenfalls ist noch eine Menge Phantasie in dem Produkt "R" und somit in der Aktie.
karo
Karo-AS oder Karo-line?
Der Kurs schleicht gegen Norden, weil die Tagung, auf der ADVR 2 Vorträge hält, immer näher kommt. Keiner will, wenn es vieleicht im Anschluß an die Tagung zu big NEWS kommt, den Hype versäumen!
Mir soll es recht sein, ich bin mit 0,375 eingestiegen! Dazu kommt noch ein 10%-iger Währungsgewinn!
morchel
Der Kurs schleicht gegen Norden, weil die Tagung, auf der ADVR 2 Vorträge hält, immer näher kommt. Keiner will, wenn es vieleicht im Anschluß an die Tagung zu big NEWS kommt, den Hype versäumen!
Mir soll es recht sein, ich bin mit 0,375 eingestiegen! Dazu kommt noch ein 10%-iger Währungsgewinn!
morchel
Karo 7, 
Wann genau ist die Tagung? War es 9 oder 11.Sept.?
KOnnte leider auf deiner Site nichts finden. Finde diese teilweise recht interessant. Doch mir fehlt eine aktuelle Zusammenfassung der letzten Nachrichten/Gerüchte. Um mal kurz den Überblick der aktuellen Lage zu erhalten.
karo
Wann genau ist die Tagung? War es 9 oder 11.Sept.?
KOnnte leider auf deiner Site nichts finden. Finde diese teilweise recht interessant. Doch mir fehlt eine aktuelle Zusammenfassung der letzten Nachrichten/Gerüchte. Um mal kurz den Überblick der aktuellen Lage zu erhalten.
karo
Karo sieben
Ich denke vom 8-10 September!
morchel
Ich denke vom 8-10 September!
morchel
thanx,
na dann ist ja noch ein bisschen Zeit vielleicht für eine kleine Rally ? Schaun ma mal.
karo
na dann ist ja noch ein bisschen Zeit vielleicht für eine kleine Rally ? Schaun ma mal.
karo
here we go !
karo
karo
Bin auch seit $0,39 drin und will ja mal viele News von der Tagung am 07,09,2000 erwarten.
Ich will ehrlich sein und hatte etwa 3000 DM als Zockkapital eingesetzt aber werde nicht vor 100000 DM verkaufen. Lieber habe ich einen Totalverlust der 3000 DM
So ist das ...
Ich will ehrlich sein und hatte etwa 3000 DM als Zockkapital eingesetzt aber werde nicht vor 100000 DM verkaufen. Lieber habe ich einen Totalverlust der 3000 DM
So ist das ...
Na denn wollen wir mal hoffen, dass es diese Woche noch weiter klingelt.
karo
karo
So fuer alle die Infos zu OTC werten brauche hier ein link . Mitglied werden und nutzen .
http://quotes.freerealtime.com/rt/frt/quotes?symbol=ADVR&typ…
Ist voellig kostenlos!! Man muss nur etwas englisch koennen.
MFG Rente
http://quotes.freerealtime.com/rt/frt/quotes?symbol=ADVR&typ…
Ist voellig kostenlos!! Man muss nur etwas englisch koennen.
MFG Rente
Wunderbar, dass hier ADVR diskutiert wird.
Vielleicht interessiert es Euch: Habe vor drei Jahren 20 K ADVR zu 24 gekauft...Und von wem kam der Tipp:
Von der Credit Suisse...Die Dame sagte mir damals, ich solle ADVR kaufen und imHinblick auf die Rente
einfach liegenlassen, nicht beachten. inzwischen hat sich ADVR verdreifacht, erreichte zwischenzeitlich
1.75 US Dollar.
Ein erneuter Anstieg erscheint moeglich. Gestern stieg advr um fast 20 Prozent bei einem Umsatz von
ueber sechs Millionen... so ging das auch los, als ADVR auf die 1.75 ging...
Vielleicht interessiert es Euch: Habe vor drei Jahren 20 K ADVR zu 24 gekauft...Und von wem kam der Tipp:
Von der Credit Suisse...Die Dame sagte mir damals, ich solle ADVR kaufen und imHinblick auf die Rente
einfach liegenlassen, nicht beachten. inzwischen hat sich ADVR verdreifacht, erreichte zwischenzeitlich
1.75 US Dollar.
Ein erneuter Anstieg erscheint moeglich. Gestern stieg advr um fast 20 Prozent bei einem Umsatz von
ueber sechs Millionen... so ging das auch los, als ADVR auf die 1.75 ging...
http://quotes.barchart.com/texpert.asp?sym=ADVR&code=BWSDR
welche Aussagekraft liegt dahinter? jedenfalls steht alles auf 100%buy!!
karo
welche Aussagekraft liegt dahinter? jedenfalls steht alles auf 100%buy!!
karo
hoffentlich sehen das möglichst viele!
*klingelklingel*
Habe nochmal alte ADVR News durchgesehen! Mit einer Zulassung von "R" ist nicht vor Ende 2001 zu rechnen!
Hoffentlich wird die Konferenz gut (dieses Wochenende!)
morchel
Karo! habe meinen Analysenlink schon zum Teil überarbeitet. (ADVR ist dabei)
Sag mir mal wie du es findest!
*klingelklingel*
Habe nochmal alte ADVR News durchgesehen! Mit einer Zulassung von "R" ist nicht vor Ende 2001 zu rechnen!
Hoffentlich wird die Konferenz gut (dieses Wochenende!)
morchel
Karo! habe meinen Analysenlink schon zum Teil überarbeitet. (ADVR ist dabei)
Sag mir mal wie du es findest!
ADVR vorbörslich!!!
09.07.00 15:18:02 0.75 0.61 0.62 1100.00
Ein Verkauf zu 0,75
hat zwar nicht zu bedeuten, aber freuen tuts mich schon!
morchel
Quelle QT Server Datek streaming (realtimekurse)
09.07.00 15:18:02 0.75 0.61 0.62 1100.00
Ein Verkauf zu 0,75
hat zwar nicht zu bedeuten, aber freuen tuts mich schon!
morchel
Quelle QT Server Datek streaming (realtimekurse)
17:21 2 Mil stücke gehandelt und keine Kursveränderung!
ALLE scheinen nervös!
morchel
ALLE scheinen nervös!
morchel
Hi morchel,
Alle ?
Wär schön wenn die 0.6$ halten würde, auch wenn kein positives Signal von der Konferenz kommen würde. Aber ich hoffe der Dr.H. denkt auch ein bisschen an den Kurs.
karo
Alle ?
Wär schön wenn die 0.6$ halten würde, auch wenn kein positives Signal von der Konferenz kommen würde. Aber ich hoffe der Dr.H. denkt auch ein bisschen an den Kurs.
karo
Aber Interesse ist nicht zu leugnen, besonders am amerikanischen Vormittag!
2,7 mil jetzt!
morchel
2,7 mil jetzt!
morchel
Der Hype erstmal vorbei, der von der Konferenz ausging.?
Hoffentlich fallen wir nicht wieder in die 40 Cent.
karo
Hoffentlich fallen wir nicht wieder in die 40 Cent.
karo
Geduld Geduld!
Meldung von gestern!
U.S. Efforts on HIV/AIDS and Infectious Diseases
U.S. Newswire (09/08/00)
The Clinton administration has released a statement showing its strong support for United Nations Secretary-General Kofi Annan`s call for international action to fight HIV. The statement notes that the White House also backs Annan`s recommendation that health research be focused on issues that affect the majority of the world`s people. AIDS, for example, took the lives of 2.8 million people in 1999, while millions continue to die from vaccine-preventable infections and many more die from disease which still need vaccines, including AIDS and malaria. The statement also lists actions the administration has taken that support the recommendations of the U.N. Millennium Report in terms of the threat of global disease issues.
AIDS also ein oberwichiges Thema!
Quelle:http://www.idsociety.org/NNii/newsbriefs.htm
morchel
Meldung von gestern!
U.S. Efforts on HIV/AIDS and Infectious Diseases
U.S. Newswire (09/08/00)
The Clinton administration has released a statement showing its strong support for United Nations Secretary-General Kofi Annan`s call for international action to fight HIV. The statement notes that the White House also backs Annan`s recommendation that health research be focused on issues that affect the majority of the world`s people. AIDS, for example, took the lives of 2.8 million people in 1999, while millions continue to die from vaccine-preventable infections and many more die from disease which still need vaccines, including AIDS and malaria. The statement also lists actions the administration has taken that support the recommendations of the U.N. Millennium Report in terms of the threat of global disease issues.
AIDS also ein oberwichiges Thema!
Quelle:http://www.idsociety.org/NNii/newsbriefs.htm
morchel
Viral Research Corp. (Otcbb: ADVR) verkündete heute, daß Wissenschaftler entdeckt haben, daß die Flaggschiffdroge der Firma, " Produkt R, " das Wachstum des Adenovirus in der Zellkultur hemmt. Adenovirusinfektion verursacht epidemische Bindehautentzündung- (" rosafarbenes Auge "), obere und unterereatmungskrankheit und Gastroenteritis. Es gibt aktuell keine anerkannte, ungiftige Therapie für adenoviral Infektion. ....Wissenschaftler, geführt von Drs. Wenlin Huang, Jin Zhang, Qingping Jiang, Yuanen Ji, Johnfischer und Shalom Z. Hirschman,stellten ihre Entdeckungen bei der 38th jährlichen Sitzung der ansteckenden Krankheitgesellschaft von Amerika (IDSA) in New-Orleans, LA dargestellt.
Auszug, http://finance.yahoo.com/q?s=advr.ob&d=v1
Na Bitte, scheint ja eine wahre Wunderdroge zu sein.
karo
Auszug, http://finance.yahoo.com/q?s=advr.ob&d=v1
Na Bitte, scheint ja eine wahre Wunderdroge zu sein.
karo
Karo!
Wenn R wirklich so gut ist wie angekündigt, werden wir in einem Jahr im Geld schwimmen!
Dagobert Morchel
(danke fürs Mail)
Wenn R wirklich so gut ist wie angekündigt, werden wir in einem Jahr im Geld schwimmen!
Dagobert Morchel
(danke fürs Mail)
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 294 | ||
| 108 | ||
| 106 | ||
| 77 | ||
| 70 | ||
| 64 | ||
| 60 | ||
| 47 | ||
| 46 | ||
| 45 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 28 | ||
| 27 | ||
| 27 | ||
| 22 | ||
| 21 | ||
| 21 | ||
| 20 | ||
| 19 | ||
| 18 |
